Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices

Journal of Viral Hepatitis

Volumn 20, Issue 2, 2013, Pages 113-121

  Di Marco, V ^a   Calvaruso, V ^a   Grimaudo, S ^a   Ferraro, D ^a   Pipitone, R M ^a   Di Stefano, R ^a   Craxi A ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

chronic hepatitis C; cirrhosis; IL 28B; inosine triphosphatase; sustained virologic response

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; INOSINE TRIPHOSPHATE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALLELE; ANEMIA; ARTICLE; ASCITES; BRAIN DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ESOPHAGUS VARICES; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROLOGIC DISEASE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE; VASCULAR DISEASE;

AGED; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84872170205     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01637.x     Document Type: Article

References (28)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP,. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538. (Pubitemid 44307383)
2. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338. (Pubitemid 36443043)
3. Coverdale SA, Khan MH, Byth K, et al. Effects of Interferon treatment response on liver complications of chronic hepatitis C: 9-year follow up study. Am J Gastroenterol 2004; 99: 636-644. (Pubitemid 38607966)
4. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N,. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-114.
5. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587. (Pubitemid 46453759)
6. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684. (Pubitemid 351664462)
7. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
8. Craxì A,. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Liver International 2012; 32, Suppl. 1: 2-8.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
10. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and Ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
11. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and Ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
12. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
13. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against Ribavirin-induced hemolytic anemia and decrease the need for Ribavirin dose reduction. Gastroenterology 2010; 139: 1181-1189.
14. Thompson AJ, Santoro R, Piazzolla V, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011; 53: 389-395.
15. Vezali E, Aghemo A, Colombo M,. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117-2138.
16. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with Ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484-491. (Pubitemid 47336987)
17. Giannini EG, Basso M, Savarino V, Picciotto A,. Predictive value of on treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med 2009; 266: 537-546.
18. Aghemo A, Rumi MG, Monico S, et al. The pattern of pegylated interferon-alpha2b and Ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir Ther 2009; 14: 577-584.
19. Everson GT, Hoefs JC, Seeff LB, et al., for HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44: 1675-1684. (Pubitemid 44953672)
20. Fontana RJ, Sanyal AJ, Ghany MG, et al., for HALT-C Trial Group. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010; 138: 2321-2331.
21. Lok AS, Seeff LB, Morgan TR, et al., for HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148.
22. Calvaruso V, Di Marco V, Bronte F, Cabibi D, Bavetta MG, Craxì A,. Measurement of collagen proporzionate area in HCV cirrhosis has major clinical correlates. Hepatology 2010; 52 (Suppl 4): 1582 A.
23. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90.
24. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
25. Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
26. McHutchison JG, Lawitz EJ, Shiffman ML, et al. IDEAL Study Team. Peg-Interferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
27. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231. (Pubitemid 41772537)
28. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-1256.